Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$3.37
$0.00(0.00%)
At close: 4:00 PM EDT
$3.37
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.12 - $71.50
Previous CloseN/A
Volume9.08K
Average Volume (3M)56.22K
Market Cap
$5.46M
Enterprise Value$16.22
Total Cash (Recent Filing)$1.96M
Total Debt (Recent Filing)$6.09M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.72
Shares Outstanding1,659,554
10 Day Avg. Volume38,648
30 Day Avg. Volume56,215
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary CAB PlatformBioAtla’s CAB platform is a durable competitive asset: tumor‑selective activation can materially improve therapeutic index and tolerability, creating differentiated clinical profiles and stronger partnership/licensing prospects that support program value and strategic optionality over months to years.
Positive Gross Profit On Small BasePositive gross profit indicates the company’s underlying candidate economics can cover direct costs at current activity levels. While overall losses persist, sustainable gross margins improve the odds that, if revenues scale via partnerships or approvals, operating margins can become viable versus peers over the medium term.
Board & Governance ApprovalShareholder ratification of directors and auditor and advisory approval of pay strengthen governance, aiding credibility with partners and investors. Board continuity and independent audit oversight reduce execution risk and support smoother capital-raising and collaboration negotiations over the coming quarters.
Bears Say
Heavy Cash BurnPersistent multi‑tens of millions in negative operating and free cash flow creates ongoing financing needs. This structural cash burn narrows runway, raises the likelihood of dilutive equity raises or dependence on partner milestone timing, and constrains program progression and hiring flexibility over the next several quarters.
Negative Shareholders' Equity & Shrinking AssetsA shift to negative equity and a materially reduced asset base weakens financial resilience and limits borrowing or non-dilutive funding options. This structural balance‑sheet deterioration elevates insolvency risk under stress and reduces strategic flexibility for partnerships or M&A responses in the medium term.
Very Low And Declining RevenueA minimal and sharply declining revenue base implies limited internal funding from operations and high reliance on external milestones or financings. Low recurring revenue reduces operating leverage and magnifies the impact of any program delays, making near-term self‑funding of clinical activities unlikely.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $3.12 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $5.46M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Bioatla, Inc.’s earnings last quarter?
Currently, no data Available
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Overvalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,659,554 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
27.13% Insiders
11.81% Mutual Funds
― Other Institutional Investors
59.51% Public Companies and
Individual Investors